Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events

Side navigation

Welcome Guest!

Published September 15, 2021

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 4: Managing Immune Checkpoint Inhibitor Adverse Events, will cover the presentations, diagnosis and management of adverse events resulting from immune checkpoint inhibitor treatments.

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Jason Luke, MD, FACP
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Immunology and Immunotherapy Program
University of Pittsburch Medical Center, Pittsburgh, PA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Recognition, Frequency and Kinetics of Immune-Related Toxicities	Identify the immune-related toxicities associated with checkpoint inhibition. Classify severity of immune related side effects. Describe the kinetics of immune-related toxicities of immune checkpoint inhibition. Distinguish immune-related side effects from those related to disease progression. Recognize and manage hyperprogression. Manage concurrent multiple adverse events. Manage immunosuppressive medications used to treat adverse events.
Management of Immune-Related Colitis	Describe how to diagnose immune-related colitis. Describe the frequency and time to development of immune-related colitis associated with distinct immunotherapeutic drugs. Manage grade 1/2 colitis and steroid refractory immune-related colitis.
Management of Immune-Related Pneumonitis	Diagnose immune-related pneumonitis. Describe the frequency of immune-related pneumonitis with distinct cancer types. Manage immune-related pneumonitis.
Management of Immune-Related Endocrinopathies	List immune-related endocrinopathies. Recognize and diagnose immune-related endocrinopathies. Treat immune-related endocrinopathies based on the severity of the toxicity. Counsel patients about long term consequences and management of endocrinopathies.
Management of Immune-Related Hepatitis	Recognize and diagnose immune-related hepatitis. Treat immune-related hepatitis based on the severity of the toxicity.
Management of Immune-Related Cutaneous Events	List immune-related cutaneous events. Recognize and diagnose immune-related cutaneous events. Treat immune-related cutaneous events based on the severity of the toxicity.
Management of Other (Rare) Immune-related Adverse Events	List rare immune-related adverse events. Recognize and diagnose rare immune-related adverse events. Treat rare immune-related adverse events based on the severity of the toxicity.
Unique aspects of IO-containing combination therapies	Describe the patterns and severity of adverse events with IO-containing combination therapies relative to the single agents. Distinguish between immune-related and other toxicities in patients receiving IO-containing combination therapies.
Chronic Toxicities Associated with Cancer Immunotherapy	List chronic toxicities of immunotherapy. Describe the time course of chronic toxicities of immunotherapy. Manage the chronic toxicities of immunotherapy.
Management of Non-Immune-Mediated Adverse Events	List non-immune-mediated adverse events. Recognize non-immune-mediated adverse events. Treat non-immune-mediated adverse events.
Management of ICB therapy in the Context of an Adverse Event	Describe when ICB therapy can be continued, reduced or discontinued in the face of toxicity. Describe when ICB therapy can be reinstated following management of toxicity.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Date of CE Release: September 15, 2021
Date of CE Expiration: September 15, 2023
Approximate Time to Complete: 60 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 75% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM for physicians, 1.00 contact hours for nurses and 1.00 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
UAN: JA4008163-9999-21-175-H04-P / JA4008163-9999-21-175-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Relationship: Commercial Entity
Michael	Dougan	Consultant: Genentech-Roche, Tillotts Pharma, Partner Therapeutics
Tiffany	Klopp	NA
Lisa	Kottschade	Consultant: BMS
Claire	Leischer	NA
Jason	Luke	Consulting: Fstar, RefleXion, Xilio Abbvie, Alnylam, Bayer, Bristol-Myers Squibb, Checkmate, Crown, Cstone, Eisai, EMD Serono, Flame, Genentech, Gilead, Kadmon, KSQ, Janssen, Immunocore, Inzen, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, TRex, Werewolf, Xencor; Contracted Research: AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb (IIT & industry), Corvus, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Numab, Replimmune, Rubius, Spring bank, Synlogic, Takeda, Trishula, Tizona, Xencor
Jose	Lutzky	Consultant: Castle, Kimera Labs,Regeneron, Replimune, Iovance; Contracted Research: BMS, Replimune, Novartis, Regeneron. Immunocore, Iovance
Scott	McGee-Plys	NA
Jill	Wall	NA
Mary Susan	Warsey	NA

Method of Participation and Request for Credit
During the period 9/15/21 through 9/15/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.